加拿大和萨斯喀彻温同意4 000万美元的协议,以提高稀有疾病的药物覆盖率。 Canada and Saskatchewan agree on $40 million deal to improve drug coverage for rare diseases.

加拿大和萨斯喀彻温政府商定了一项4 000万美元的协议,以提高罕见疾病的药物覆盖率,为罕见癌症和肾病患者提供Poteligeo、Epkinly和Oxlumo等治疗。 The Canadian and Saskatchewan governments have agreed on a $40 million deal to improve drug coverage for rare diseases, providing access to treatments like Poteligeo, Epkinly, and Oxlumo for patients with rare cancers and kidney conditions. 这项协议是为期三年的15亿美元的较大联邦投资的一部分,目的是增加加拿大各地获得治疗、早期诊断和罕见疾病筛查的机会。 This agreement is part of a larger $1.5 billion federal investment over three years to enhance access to treatments, early diagnosis, and screening for rare diseases across Canada.